Analysts Set Biogen Inc. (NASDAQ:BIIB) Price Target at $220.57

Shares of Biogen Inc. (NASDAQ:BIIB) have received an average recommendation of “Moderate Buy” from the thirty-two brokerages that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation, seventeen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $223.3571.

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group boosted their target price on Biogen from $245.00 to $248.00 and gave the company a “buy” rating in a report on Thursday. TD Cowen increased their price target on Biogen from $215.00 to $225.00 and gave the stock a “buy” rating in a report on Thursday. Barclays lifted their price objective on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Wednesday. UBS Group upped their price objective on shares of Biogen from $225.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd.

Biogen Trading Down 2.4%

BIIB opened at $202.95 on Monday. Biogen has a 52 week low of $124.56 and a 52 week high of $219.72. The company has a quick ratio of 2.41, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. The firm has a market cap of $29.99 billion, a price-to-earnings ratio of 35.92, a price-to-earnings-growth ratio of 6.43 and a beta of 0.16. The business’s 50 day moving average is $201.23 and its two-hundred day moving average is $190.60.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business’s revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, research analysts predict that Biogen will post 12.49 EPS for the current year.

Institutional Investors Weigh In On Biogen

Hedge funds have recently added to or reduced their stakes in the company. Reflection Asset Management acquired a new stake in shares of Biogen in the 4th quarter valued at approximately $25,000. WPG Advisers LLC grew its holdings in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the period. First Horizon Corp purchased a new position in Biogen in the fourth quarter worth $30,000. Root Financial Partners LLC raised its position in Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. acquired a new stake in Biogen in the fourth quarter valued at $34,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen reported second-quarter revenue of $2.74 billion, up 3.4% year over year and ahead of consensus estimates of approximately $2.46 billion. Growth was led by newer products and the company’s growth portfolio, helping adjusted EPS reach $3.60 versus the $2.94 analyst estimate. Biogen beats quarterly estimates as newer drugs drive growth
• Positive Sentiment: Management raised its revenue outlook and highlighted continued momentum in newer medicines and strategic acquisitions, supporting the view that Biogen is gradually reducing its reliance on older products. Biogen raises revenue outlook as growth portfolio drives Q2 beat
• Positive Sentiment: Several analysts became more constructive after the results. TD Cowen raised its price target to $225 and upgraded the stock to Buy, while Morgan Stanley increased its target to $231, although it retained an Equal Weight rating. Barclays also expects the shares to rise.
• Neutral Sentiment: Wedbush raised its price target from $201 to $215 but maintained a Neutral rating, and Piper Sandler reaffirmed its Buy rating. Zacks upgraded Biogen from Strong Sell to Hold, indicating improving sentiment but not broad analyst conviction.
• Negative Sentiment: Reported profitability deteriorated substantially. Second-quarter net income fell to $97.5 million, while diluted EPS from continuing operations declined to $0.66 from $4.33 a year earlier; first-half net income also dropped to $417 million from $875.3 million. The sharp gap between revenue growth and reported earnings is raising concerns that profitability may be peaking. Biogen earnings and profitability analysis

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.